Literature DB >> 15624549

Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services.

Janetta M Astone1, Shiela M Strauss, Holly Hagan, Don C Des Jarlais.   

Abstract

The hepatitis C virus (HCV) continues to penetrate populations within the United States, especially within the drug-abusing population. Therefore, drug users need access to HCV testing and medical care, and drug treatment programs are well situated to provide these services. Because directors of these programs are gatekeepers who can influence decisions about service provision, their beliefs about the value of providing particular services for drug treatment program patients are of considerable importance. Directors of 121 outpatient drug treatment programs throughout the United States responded to an in-depth telephone survey that included questions on their beliefs about providing HCV services in drug treatment programs. We constructed an eight-item scale to examine these beliefs and investigated the relationship between them and the actual HCV services offered. Overall, directors were moderately supportive of the provision of HCV medical services (on-site or through referral) during drug treatment. Our findings indicate that there is a positive significant relationship between director's beliefs and the provision of HCV antibody testing, follow-up testing, and the provision of HCV medication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15624549     DOI: 10.1081/ada-200037544

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  5 in total

1.  Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problems.

Authors:  Anita Palepu; Debbie M Cheng; Theresa Kim; David Nunes; John Vidaver; Julie Alperen; Richard Saitz; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2006-08-14

2.  Retention in buprenorphine treatment is associated with improved HCV care outcomes.

Authors:  B L Norton; A Beitin; M Glenn; J DeLuca; A H Litwin; C O Cunningham
Journal:  J Subst Abuse Treat       Date:  2017-01-27

Review 3.  Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Authors:  Brianna L Norton; Matthew J Akiyama; Philippe J Zamor; Alain H Litwin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

4.  Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR.

Authors:  Marzieh Jamalidoust; Mandana Namayandeh; Sadaf Asaei; Nasrin Aliabadi; Mazyar Ziyaeyan
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

5.  Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services.

Authors:  Jemima A Frimpong; Thomas D'Aunno
Journal:  Subst Abuse Treat Prev Policy       Date:  2016-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.